Integrating Clinical Pharmacokinetics, Pharmacogenetics, and Quantitative Cytochrome P450 Polymorphic Gene Drug-Drug Interactions (DDIs)
Linares, O.A.; Fudin, J.; Boston, R.C.; Daly, A.L.
Pain Physician 18(3): E439-E441
2015
ISSN/ISBN: 2150-1149 PMID: 26000695 Document Number: 681701
Document emailed within 1 workday
Related Documents
Kanarkowski, R.; Targońska, A. 1978: Various problems of clinical psychopharmacology (pharmacokinetics and drug interactions) Psychiatria Polska 12(2): 263-272Staiger, C. 1982: Oral contraceptives. Clinical pharmacology, pharmacokinetics and drug interactions Münchener Medizinische Wochenschrift 124(20): 495-498
Kohl, C.; Steinkellner, M. 2000: Prediction of pharmacokinetic drug/drug interactions from in vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants Drug Metabolism and Disposition: the Biological Fate of Chemicals 28(2): 161-168
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Estler, C.J. 1984: Drug interactions of central nervous system active drugs. 3: Drug interactions of anticonvulsants and antiparkinson agents Fortschritte der Medizin 102(6): 129-132
Sellers, E.M. 1984: Ethanol-psychotropic drug interactions: pharmacokinetics Psychopharmacology Bulletin 20(3): 497-499
Sawada, Y.; Ohtani, H. 2001: Pharmacokinetics and drug interactions of antidepressive agents Nihon Rinsho. Japanese Journal of Clinical Medicine 59(8): 1539-1545
Brøsen, K. 1991: The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs Ugeskrift for Laeger 153(6): 417-422
Crismon, M.L. 1998: Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease PharmacoTherapy 18(2 Part 2): 47-54; Discussion: 79-82
Bachmann, K.; Sullivan, T.J.; Fraiwat, T. 1988: Quantitative comparisons of pharmacokinetic drug interactions: a probabilistic approach Methods and Findings in Experimental and Clinical Pharmacology 10(11): 711-716
Pichard, L.; Fabre, J.M.; Domergue, J.; Fabre, G.; Saint-Aubert, B.; Mourad, G.; Maurel, P. 1991: Molecular mechanism of cyclosporine a drug interactions: inducers and inhibitors of cytochrome P450 screening in primary cultures of human hepatocytes Transplantation Proceedings 23(1 Part 2): 978-979
Blardi, P. 1997: Pharmacogenetics: pharmacokinetics and clinical implications Recenti Progressi in Medicina 88(1): 46-55
Kumar, S.; Rao, P.S.S.; Earla, R.; Kumar, A. 2015: Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems Expert Opinion on Drug Metabolism and Toxicology 11(3): 343-355
Scarsi, K.K.; Darin, K.M.; Chappell, C.A.; Nitz, S.M.; Lamorde, M. 2016: Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV Drug Safety 39(11): 1053-1072
Pathak, J.; Kiefer, R.C.; Chute, C.G. 2013: Using linked data for mining drug-drug interactions in electronic health records Studies in Health Technology and Informatics 192: 682-686
Palmer, J.D.; Bressler, R. 1974: Drug--drug interactions. A general discussion about how and where drugs may interact in the body Arizona Medicine 31(2): 89-93
Hensjö, L.O. 1995: A new classification introduced in Fass (Swedish Drug Index). a simple way for assessment of drug interactions Lakartidningen 92(38): 3479-3480
Furue, H. 1986: Application and problems of combination drug therapy--drug interactions of antineoplastic agents and antibiotics Nihon Rinsho. Japanese Journal of Clinical Medicine 44(4): 942-946
Wagner, J.G.; Weidler, D.J.; Lin, Y.J. 1976: New method for detecting and quantitating pharmacokinetic drug-drug interactions applied to ethanol-propranolol Research Communications in Chemical Pathology and Pharmacology 13(1): 9-18
Phillips, D.R.; White, R.J.; Trist, H.; Cullinane, C.; Dean, D.; Crothers, D.M. 1990: New insight into drug-DNA interactions at individual drug binding sites probed by RNA polymerase during active transcription of the DNA Anti-Cancer Drug Design 5(1): 21-29